Caricamento...
Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil
Patients with metastatic colorectal cancer (mCRC) are surviving longer now than ever before, but mortality rates are still high and more effective therapies are clearly needed. For patients with disease that is refractory to fluoropyrimidines, oxaliplatin, irinotecan, and biologic agents targeting t...
Salvato in:
| Pubblicato in: | Cancer Manag Res |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5635852/ https://ncbi.nlm.nih.gov/pubmed/29056855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S113320 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|